US FDA approves Celcuity's breast cancer drug

AstraZeneca PLC
Celcuity Inc.
Eli Lilly and Company
Pfizer Inc.
Novan, Inc.

AstraZeneca PLC

AZN

0.00

Celcuity Inc.

CELC

0.00

Eli Lilly and Company

LLY

0.00

Pfizer Inc.

PFE

0.00

Novan, Inc.

NOVN

0.00

July 14 (Reuters) - The U.S. Food and Drug Administration has approved Celcuity's CELC.O drug for an advanced form of breast cancer, the regulator said on Tuesday, making it the company's first product to gain market entry.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.